How Recursion is leading a new era of AI-driven drug discovery AI drug discovery is not a new phenomenon – but it is evolving at an almost dizzying pace. Recursion is one of the earliest innovators in ...

Keep up the assault, pull back when it burrows under to dodge lightning blast, then refocus your attack when it tries to take ...

Find out the direct holders, institutional holders and mutual fund holders for Recursion Pharmaceuticals, Inc. (RXRX).

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

The last time I spoke about Recursion Pharmaceuticals (RXRX), it was with a Seeking Alpha article entitled "Recursion: "Hold" Rating Based On Initial REC-4881 FAP Treatment Data." With respect to this ...

Follow this section to personalize your feed and get instant alerts. WHY FOLLOW? Update your preferences in Account Settings Personalized Content Follow this tag to personalize your feed and get ...

The stock of Recursion Pharmaceuticals (RXRX) has gained >15% in early trading today, as the AI-driven drug discovery company shared a couple of notable updates. Firstly Recursion announced the ...

Recursion's co-founder and long-serving chief executive, Chris Gibson, has switched to the role of company chair, and will be succeeded in the CEO role by R&D and commercial head Najat Khan. The ...

Recursive, an AI startup founded last year, is starting to live up to its name. The company, which is trying to build AI that can improve itself, released its first model, Flint, on Wednesday. Flint ...

Ricursive Intelligence founders Anna Goldie and Azalia Mirhoseini believe more efficient AI chip design could help solve the compute crisis. The founders took the stage at TechCrunch Disrupt on ...

You're currently following this author! Click to unsubscribe from email alerts. Google may be approaching a pivotal moment in AI. In a roundtable discussion about the creation of Google's new Gemini 4 ...